Does My Insurance Cover GLP-1 Medication? A Complete Coverage Guide

How Insurance Decides Whether to Cover a GLP-1

Insurance coverage for GLP-1 receptor agonists is not automatic. Payers evaluate the FDA-approved indication on the label, your documented diagnosis codes (ICD-10), your prescriber's specialty, and whether you have tried and failed alternative treatments first. A plan that covers Ozempic (semaglutide 0.5 to 2 mg) for type 2 diabetes may still deny Wegovy (semaglutide 2.4 mg) for obesity, even though the active molecule is identical, because the two products carry different FDA-approved indications and different formulary placements. The FDA's approved labeling for Ozempic and Wegovy make this distinction explicit.

The Role of FDA Indication in Coverage Decisions

The FDA approved semaglutide 2.4 mg (Wegovy) in June 2021 specifically for chronic weight management in adults with a BMI of 30 or greater, or BMI <27 with at least one weight-related comorbidity. [1] Tirzepatide 2.5 to 15 mg (Zepbound) received a similar obesity indication in November 2023. [2] Because obesity has historically been classified differently from metabolic disease by payers, these obesity-specific labels often land on a separate, more restricted formulary tier than the diabetes-labeled versions of the same compounds.

How Formulary Tiers Affect Your Cost

Most insurers use a three-to-five tier formulary. Generic drugs sit on tier 1 with the lowest copay. Brand-name preferred drugs occupy tier 2 or 3. Specialty drugs, which include all injectable GLP-1s, typically land on tier 4 or 5, where cost-sharing can reach 30 to 40% of the retail price. At Wegovy's list price of approximately $1,349 per month, a 33% coinsurance means you could owe $445 per month even with coverage active.

Prior Authorization: What Insurers Typically Require

Prior authorization (PA) is standard for GLP-1s across nearly all commercial plans. Typical PA criteria include:

• A confirmed ICD-10 diagnosis (E11.x for type 2 diabetes, or E66.x for obesity)
• Documented BMI at or above the FDA threshold
• Evidence of lifestyle intervention attempts lasting at least three to six months
• Absence of contraindications such as personal or family history of medullary thyroid carcinoma
• Prescriber attestation that the drug is medically necessary

The American Diabetes Association 2024 Standards of Care explicitly recommends GLP-1 receptor agonists as second-line agents for type 2 diabetes when HbA1c remains above goal on metformin, which gives prescribers a strong clinical rationale to present during the PA process. [3]

Which GLP-1 Medications Are Most Commonly Covered?

Coverage rates differ by drug and by indication. The table below reflects 2024 formulary data from major commercial plan analyses.

| Drug | Brand | Primary Indication | Coverage Rate (Commercial) | |---|---|---|---| | Semaglutide 0.5 to 2 mg | Ozempic | Type 2 diabetes | High (70 to 80% of plans) | | Liraglutide 1.2 to 1.8 mg | Victoza | Type 2 diabetes | Moderate (50 to 65% of plans) | | Dulaglutide 0.75 to 4.5 mg | Trulicity | Type 2 diabetes | High (65 to 75% of plans) | | Semaglutide 2.4 mg | Wegovy | Obesity / weight management | Low-moderate (30 to 45% of plans) | | Tirzepatide 5 to 15 mg | Mounjaro | Type 2 diabetes | Moderate (50 to 60% of plans) | | Tirzepatide 2.5 to 15 mg | Zepbound | Obesity / weight management | Low (20 to 35% of plans) | | Liraglutide 3 mg | Saxenda | Obesity / weight management | Low (25 to 40% of plans) |

These estimates align with findings from the IQVIA Institute for Human Data Science and with formulary analyses published in peer-reviewed journals tracking specialty drug access.

Diabetes-Indication Coverage

Plans governed by the Affordable Care Act must cover preventive services rated A or B by the USPSTF, but GLP-1 prescriptions for active diabetes management fall under pharmacy benefits, not preventive benefits. Still, because diabetes drugs carry strong clinical backing, most large commercial plans include at least one GLP-1 on their formulary. STEP-2 (N=1,210) showed semaglutide 1 mg reduced HbA1c by 1.6 percentage points versus 0.5 percentage points for placebo at 40 weeks, supporting the drug's place in diabetes management guidelines. [4]

Obesity-Indication Coverage

Obesity-labeled GLP-1s face more resistance. A 2023 analysis found that only about 43% of large employer plans covered Wegovy or Saxenda for obesity. [5] The resistance is partly actuarial: the STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% for placebo (P<0.001), a result that translates into meaningful downstream cost savings, yet many payers still model obesity treatment as a long-term liability rather than a cost offset. [6]

Medicare and Medicaid Coverage for GLP-1s

Medicare Part D

Medicare Part D covers GLP-1s prescribed for type 2 diabetes. The Inflation Reduction Act of 2022 capped out-of-pocket drug costs for Medicare beneficiaries at $2,000 per year starting in 2025, which will meaningfully reduce annual GLP-1 costs for seniors with diabetes. [7]

Obesity-only indications remain largely excluded from Medicare Part D as of 2024. The Treat and Reduce Obesity Act, if passed, would change this, but it has not yet been enacted into law. A 2023 CMS fact sheet confirmed that weight-loss drugs classified as such are excluded from Part D coverage under current statute. [8]

Medicaid

Medicaid coverage is determined state by state. As of mid-2024, approximately 30 states cover at least one obesity-labeled GLP-1 for Medicaid enrollees meeting specific BMI and comorbidity criteria. States including North Carolina, Illinois, and Colorado have expanded coverage, while others restrict access strictly to diabetes indications. The Kaiser Family Foundation State Health Facts tracks state-level Medicaid drug benefit policies in real time.

How Programs Like Calibrate Manage Insurance

Calibrate is a metabolic health program that pairs GLP-1 prescriptions with behavioral coaching. The program does not replace your insurance; it works alongside whatever commercial or employer-based plan you carry. Whether your GLP-1 prescription gets covered depends entirely on your individual plan's formulary and your qualifying diagnosis.

What Calibrate Helps With

Calibrate's clinical team assists with prior authorization paperwork, documentation of metabolic comorbidities, and appeals if a first PA request is denied. The program requires members to have a BMI of 30 or above, or BMI of 27 or above with a qualifying condition such as hypertension, dyslipidemia, or type 2 diabetes. This documentation directly maps to the criteria most commercial payers use when evaluating PA requests for obesity-indication GLP-1s.

What Calibrate Does Not Control

No telehealth program, including Calibrate, can override a payer's formulary exclusions. If your employer plan has categorically excluded weight-loss medications, or if you are on Medicare Part D without a diabetes diagnosis, the program's clinical support will not change the payer's decision. In that scenario, your options are manufacturer savings programs, compounded semaglutide (with important caveats about FDA oversight), or appeal through your state's external review process.

Steps to Take Before Filling Your First GLP-1 Prescription

Acting strategically before your prescription hits the pharmacy counter can prevent a surprise denial or a $1,300 charge.

Step 1: Pull Your Plan's Formulary

Your insurer's formulary is a public document. Log in to your plan's member portal or call the pharmacy benefits number on your insurance card. Search specifically for the brand name of the drug your prescriber intends to prescribe. Check the tier, any quantity limits (most plans cap GLP-1s at a 30-day supply per fill), and whether a PA is required.

Step 2: Confirm Your Diagnosis Codes

Your prescriber must submit the correct ICD-10 code. E11.9 (type 2 diabetes without complications) supports coverage for Ozempic or Mounjaro. E66.01 (morbid obesity due to excess calories) or E66.09 supports Wegovy or Zepbound. A mismatch between the drug's FDA indication and your submitted diagnosis code is one of the most common reasons for denial.

Step 3: Complete Prior Authorization Proactively

Ask your prescriber to initiate the PA before you go to the pharmacy. The PA process takes between 3 and 15 business days at most commercial plans. The FDA's Drug Shortages database is also worth checking at this step, as supply constraints on Wegovy and Zepbound have intermittently delayed dispensing. [9]

Step 4: Apply for Manufacturer Savings Cards

If your plan covers the drug but leaves you with high cost-sharing:

• Novo Nordisk's Wegovy savings card reduces out-of-pocket costs to as low as $25 per month for eligible commercially insured patients.
• Eli Lilly's Zepbound savings card offers a similar reduction for commercially insured members.

These cards are not available to Medicare or Medicaid beneficiaries, per federal anti-kickback provisions.

What to Do If Your GLP-1 Claim Is Denied

A denial is not a final answer. The ACA requires all plans to provide a clear appeals process, and external review by an independent organization is available if internal appeals fail. [10]

Internal Appeal

File within the timeframe on your denial letter, typically 30 to 180 days. Include:

• A letter of medical necessity from your prescriber citing the relevant trial data (STEP-1, SURMOUNT-1) and current clinical guidelines
• Lab values showing HbA1c, fasting glucose, or lipid panel results
• Records documenting prior lifestyle interventions
• Your BMI measurement from a recent clinical visit

The Endocrine Society's 2023 Clinical Practice Guideline on Obesity Pharmacotherapy states: "Pharmacotherapy for obesity should be offered to individuals with a BMI of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher in the presence of at least one weight-related comorbidity, in conjunction with lifestyle interventions." Quoting this language in an appeal letter gives the reviewer a named guideline to cite in any coverage exception they approve. [11]

External Review

If your internal appeal is denied, you have the right to request external review by an Independent Review Organization (IRO). IRO reviewers are independent clinicians who apply medical evidence rather than plan policy. Roughly 40 to 60% of external reviews for specialty drug denials result in coverage being granted, based on state insurance department data from California and New York.

Step Therapy Challenges

Some plans require you to try and fail an older drug before covering a GLP-1. For diabetes, this often means demonstrating inadequate glycemic control on metformin. For obesity, it may mean a documented trial of a lower-cost agent such as orlistat or phentermine-topiramate. The American Association of Clinical Endocrinology's 2023 Consensus Statement acknowledges that step therapy protocols may delay access to first-line agents for high-risk patients. [12] Your prescriber can request a step therapy exception if you have a contraindication or documented intolerance to the required prior agent.

Compounded Semaglutide: A Coverage Workaround With Caveats

During the 2022 to 2024 shortage period, FDA-registered 503B outsourcing facilities legally compounded semaglutide. Compounded products are not FDA-approved and are not covered by insurance. They are priced significantly lower, often $200 to $400 per month, but the FDA has issued warnings about quality and dosing variability in compounded GLP-1 products. [13]

The FDA removed semaglutide from its drug shortage list in 2024, meaning 503A and 503B pharmacies are no longer permitted to compound semaglutide copies under shortage exemptions. Patients currently on compounded semaglutide should discuss the transition to an FDA-approved product with their prescriber. [14]

The Clinical Case for Coverage: Why Evidence Should Matter to Your Insurer

Payers make coverage decisions on clinical and actuarial grounds. Presenting the clinical evidence directly in your appeal letter can shift the calculus.

Weight Loss Outcomes

SURMOUNT-1 (N=2,539) showed tirzepatide 15 mg produced 20.9% mean body weight reduction at 72 weeks versus 3.1% for placebo (P<0.001). [15] These numbers rival bariatric surgery outcomes for some patients, and bariatric surgery is widely covered by commercial plans because payers recognize its long-term cost savings.

Cardiovascular Risk Reduction

The SELECT trial (N=17,604) found that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in adults with obesity and established cardiovascular disease but without diabetes, over a mean follow-up of 34.2 months. [16] The FDA approved a cardiovascular risk-reduction indication for Wegovy in March 2024, which gives prescribers and patients an additional coverage argument that extends beyond weight loss. [17]

The Endocrine Society has stated: "The cardiovascular benefits of GLP-1 receptor agonists observed in large outcomes trials support their use as a preferred agent in patients with type 2 diabetes and established or high-risk cardiovascular disease." [18]

Employer-Sponsored Plans: A Faster Path to Coverage Change

If your employer's self-insured plan excludes GLP-1s for obesity, you have a direct channel that individual market enrollees do not: your HR department. Self-insured employers set their own drug benefits and can add or remove exclusions during open enrollment benefit design. Presenting HR with the SELECT cardiovascular outcome data and the long-term cost modeling from a benefits consultant has led several large employers to add obesity drug coverage since 2022.

A 2024 KFF Employer Health Benefits Survey found that 18% of large employers (200 or more workers) covered at least one GLP-1 for obesity in 2023, up from under 5% in 2021. [19] That trajectory suggests continued expansion, especially given the new cardiovascular indication.